<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">

<head>
	<title>BromSite&trade;</title>
	<meta http-equiv="Content-Type" content="text/html; charset=utf-8">

	<style type="text/css">
		/* Fix for Yahoo */
		strong {
			font-weight: bold;
		}
		ul, ol {
			margin-bottom: 16px;
		}

		img {
			max-width: 100%;

		}
		img.real-width-img {
			max-width: none;
		}
		.mobile-pad {
			color:#3d3963; background-color:#ffffff; font-family: Arial, Helvetica,Verdana; padding-left:15px; padding-right:15px;
		}

		@media only screen and (max-width: 480px) {
			body {
				width: 100% !important;
				margin: 0;
				padding: 0;
			}
			/* mobile-specific CSS styles go here */
			table[class=contenttable] {
				width: 100% !important;
			}
			td[class="headercell"] {
				height: auto !important;
				line-height: inherit !important;
			}
			.hide-mobile {
				display: none !important;
			}
			.show-mobile {
				display: block !important;
				max-height: none !important;
			}

			table.show-mobile {
				display: table !important;

			}
			td[class="content"],
			td[class="footer"] {
				padding: 0 10px !important;
			}
			sup {
				-webkit-text-size-adjust: none;
				-moz-text-size-adjust: none;
			}
			.override-mobile-linking,
			.override-mobile-linking a {
				color: #231f20 !important;
				text-decoration: none;
			}
			img.content-mobile-image-max-width {
				width: 100%;
				height: auto;
			}

			img {
				max-width: 100%;

			}
		}

			@media only screen and (max-width: 320px) {
				.mobile-pad {
					padding-left: 8px !important;
					padding-right: 8px !important;
				}

				.mobile-pad-img {
					padding-left: 0px !important;
					padding-right: 0px !important;
				}

			}
	</style>

	<!--[if gte mso 9]>
	<style type="text/css">
		sup {
			font-size: 13px !important;
		}
	</style>
	<![endif]-->
	</head>
	<body style="margin:0; -webkit-text-size-adjust:none;">
		<table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#f3f3f9" style="background-color:#f3f3f9;">
			<tr>
				<td>
					<table class="contenttable" width="700" align="center" border="0" cellspacing="0" cellpadding="0" bgcolor="ffffff" style="color:#231f20; background-color:#ffffff; font-family: Arial, Helvetica,Verdana;">
						<tr>
							<td valign="top">
								<div class="hide-mobile">
									<table class="contenttable hide-mobile" width="100%" border="0" cellspacing="0" cellpadding="0" bgcolor="ffffff" style="color:#231f20; background-color:#ffffff; padding-left:25px; padding-right:25px; font-family: Arial, Helvetica,Verdana;">
										<tr>
											<td>
												<br>
												<a href="http://www.bromsite.com/?utm_source=eth-direct&utm_medium=email&utm_content=BromLogo&utm_campaign=IntroducingBrom" target="_blank"><img alt="BromSite&trade; logo" src="images/brom-logo.png" /></a>
												<br><br>
											</td>
											<td align="right">
												<br>
												<a href="http://www.bromsite.com/?utm_source=eth-direct&utm_medium=email&utm_content=BromLogo&utm_campaign=IntroducingBrom" target="_blank"><img alt="Now Available" src="images/now-available.png" /></a>
												<br><br>
											</td>
										</tr>
									</table>
								</div>
								<div class="show-mobile" style="display:none;max-height:0px;overflow:hidden;">
									<table align="center" class="mobile-pad show-mobile" border="0" cellspacing="0" cellpadding="0" bgcolor="ffffff" style="color:#231f20; background-color:#ffffff; padding-left:25px; padding-right:25px; font-family: Arial, Helvetica,Verdana;display:none;">
										<tr>
											<td align="center">
												<br><br>
												<a href="http://www.bromsite.com/?utm_source=eth-direct&utm_medium=email&utm_content=BromLogo&utm_campaign=IntroducingBrom" target="_blank"><img alt="BromSite&trade; logo" src="images/brom-logo.png"  /></a>
												<br><br>
												<a href="http://www.bromsite.com/?utm_source=eth-direct&utm_medium=email&utm_content=BromLogo&utm_campaign=IntroducingBrom" target="_blank"><img alt="Now Available" src="images/now-available.png" /></a>
												<br><br>
											</td>
										</tr>
									</table>
								</div>
								<div class="hide-mobile">
									<table class="contenttable hide-mobile" align="center" width="100%" border="0" cellspacing="0" cellpadding="0" bgcolor="ffffff" style="color:#3d3963; background-color:#ffffff; font-family: Arial, Helvetica,Verdana; display:block;">
										<tr style="background:#4a4956;">
										  <td align="right" colspan="2" style="padding-right:15px; padding-top:8px; padding-bottom:8px; font-size:12px;">
										    <a href="https://www.bromsite.com/pdf/BromSitePI.pdf?utm_source=eth-direct&utm_medium=email&utm_content=PI&utm_campaign=IntroducingBrom " target="_blank" style="text-decoration:underline; color:#ffffff;">Prescribing Information</a>  <a href="http://www.bromsite.com/hcp-important-safety-information/?utm_source=eth-direct&utm_medium=email&utm_content=ISI&utm_campaign=IntroducingBrom" target="_blank" style="text-decoration:underline; color:#ffffff;">Important Safety Information</a>
										  </td>
										</tr>
										<tr>
											<td>
												<img alt="BromSite&trade; for your cataract surgery patients" src="images/brom-6-hero.png" style="display:block;" width="100%" />
											</td>
										</tr>
										<tr>
											<td>
												<a href="http://www.bromsite.com/?utm_source=eth-direct&utm_medium=email&utm_content=cta1&utm_campaign=IntroducingBrom" target="_blank"><img alt="Learn more at bromsite.com" src="images/brom-6-hero-2.png" style="display:block;" width="100%" /></a>
											</td>
										</tr>
									</table>
								</div>
								<div class="show-mobile" style="display:none;max-height:0px;overflow:hidden;">
									<table align="center" class="mobile-pad-img show-mobile" width="100%" border="0" cellspacing="0" cellpadding="0" bgcolor="ffffff" style="display:none;">
										<tr style="background:#4a4956;">
										  <td align="center" colspan="2" style="padding-right:15px; padding-top:8px; padding-bottom:8px; font-size:12px;">
										    <a href="https://www.bromsite.com/pdf/BromSitePI.pdf?utm_source=eth-direct&utm_medium=email&utm_content=PI&utm_campaign=IntroducingBrom " target="_blank" style="text-decoration:underline; color:#ffffff;">Prescribing Information</a>  <a href="http://www.bromsite.com/hcp-important-safety-information/?utm_source=eth-direct&utm_medium=email&utm_content=ISI&utm_campaign=IntroducingBrom" target="_blank" style="text-decoration:underline; color:#ffffff;">Important Safety Information</a>
										  </td>
										</tr>
										<tr>
											<td align="center">
												<img alt="BromSite for your cataract surgery patients" src="images/brom-6-hero-mbl.png" width="100%" />
											</td>
										</tr>
										<tr>
											<td>
												<a href="http://www.bromsite.com/?utm_source=eth-direct&utm_medium=email&utm_content=cta1&utm_campaign=IntroducingBrom" target="_blank"><img alt="button: learn more at bromsite.com" src="images/brom-6-hero-mbl-2.png" width="100%" /></a>
											</td>
										</tr>
									</table>
								</div>
								<div class="hide-mobile">
									<table class="contenttable hide-mobile" align="center" width="100%" border="0" cellspacing="0" cellpadding="0" bgcolor="ffffff" style="color:#3d3963; background-color:#ffffff; font-family: Arial, Helvetica,Verdana; padding-left:25px; padding-right:25px;">
										<tr>
											<td align="center">
												<br>
												<p style="text-align:left;"><strong>Defend against ocular pain and treat inflammation with the penetrating power of BromSite<span style="font-size:11px; line-height:0; vertical-align:4px;">&trade;</span> formulated with the DuraSite<span style="font-size:11px; line-height:0; vertical-align:4px;">&reg;</span> delivery system.<span style="font-size:11px; line-height:0; vertical-align:4px;">1</span></strong></p>
												<p style="text-align:left;">BromSite&trade; is the first and only topical NSAID indicated to prevent ocular pain after cataract surgery.<span style="font-size:11px; line-height:0; vertical-align:4px;">1</span> Formulated with the DuraSite<span style="font-size:11px; line-height:0; vertical-align:4px;">&reg;</span> delivery system to increase ocular retention time, complete coverage is ensured with twice daily dosing.<span style="font-size:11px; line-height:0; vertical-align:4px;">1,2,3,4,5</span></p>
												<a href="https://www.activatethecard.com/7388/" target="_blank"><img alt="Savings Button" src="images/button-savings.png" /></a>
											</td>
										</tr>
										<tr>
											<td>
												<br>
												<strong>Indications and Usage</strong>
												<br><br>
												<span style="color:#2c2d2e;">BromSite&trade; (bromfenac ophthalmic solution) 0.075% is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery.</span>
												<br><br>
												<strong>Important Safety Information</strong>
												<br><br>
												<span style="color:#2c2d2e;">&bull; <strong style="color:#3d3963;">Slow or Delayed Healing:</strong> All topical nonsteroidal anti-inflammatory drugs (NSAIDs), including BromSite&trade;, may slow or delay healing. Topical corticosteroids are also known to slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems.</span>
												<br><br>
												<span style="color:#3d3963; font-weight:bold;">See additional Important Safety Information below.</span>
											</td>
										</tr>
									</table>
									<table class="contenttable hide-mobile" align="center" width="100%" border="0" cellspacing="0" cellpadding="0" bgcolor="ffffff" style="color:#2c2d2e; background-color:#ffffff; font-family: Arial, Helvetica,Verdana; padding-left:25px;">
										<tr>
										  <td align="right">
												<br>
										    <img alt="BromSite icon 1" src="images/brom-blue.png"  />
										  </td>
										</tr>
									</table>
									<table class="contenttable hide-mobile"  width="100%" border="0" cellspacing="0" cellpadding="0" bgcolor="ffffff" style="color:#3d3963; background-color:#ffffff; font-family: Arial, Helvetica,Verdana; padding-left:25px; padding-right:25px;">
										<tr>
											<td>
												<br>
												The DuraSite<span style="font-size:11px; line-height:0; vertical-align:4px;">&reg;</span> polymer enhances viscosity to increase ocular retention time and reduce medication loss due to blinking and tearing. As DuraSite<span style="font-size:11px; line-height:0; vertical-align:4px;">&reg;</span> mixes with the tear film, the polymer matrix releases bromfenac, which rapidly diffuses across the cornea.<span style="font-size:11px; line-height:0; vertical-align:4px;">3,5</span> The extended release results in improved absorption of bromfenac.<span style="font-size:11px; line-height:0; vertical-align:4px;">3</span>
												<br><br>
												<a href="https://www.bromsite.com/?utm_source=eth-direct&utm_medium=email&utm_content=Learn&utm_campaign=IntroducingBrom#about" target="_blank" style="color:#c64d36; text-decoration:underline; text-decoration:none;"><span style="text-decoration:underline;">Learn more about BromSite&trade;, formulated with the DuraSite</span><sup style="font-size:11px; line-height:0; vertical-align:4px; color:#c64d36; text-decoration:none;">&reg;</sup> <span style="text-decoration:underline;">delivery system.</span></a>
												<br><br>
												<span style="font-weight:bold; color:#3d3963;">Important Safety Information (continued)</span>
												<br><br>
												&bull; <strong>Potential for Cross-Sensitivity:</strong> There is the potential for cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other NSAIDs, including BromSite&trade;. Therefore, caution should be used when treating individuals who have previously exhibited sensitivities to these drugs.
												<br><br>
												&bull; <strong>Increased Bleeding Time of Ocular Tissue:</strong> With some NSAIDs, including BromSite&trade;, there exists the potential for increased bleeding time due to interference with platelet aggregation. There have been reports that ocularly applied NSAIDs may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery. It is recommended that BromSite&trade; be used with caution in patients with known bleeding tendencies or who are receiving other medications which may prolong bleeding time.
												<br><br>
												<strong>See additional Important Safety Information below.</strong>
											</td>
										</tr>
									</table>
									<table class="contenttable hide-mobile" width="100%" border="0" cellspacing="0" cellpadding="0" bgcolor="ffffff" style="color:#2c2d2e; background-color:#ffffff; font-family: Arial, Helvetica,Verdana; padding-left:25px;">
										<tr>
										  <td align="right">
												<br><br>
										    <img alt="BromSite icon 2" src="images/icon-pain.png"  />
										  </td>
										</tr>
									</table>
									<table class="contenttable" width="100%" border="0" cellspacing="0" cellpadding="0" bgcolor="ffffff" style="color:#3d3963; background-color:#ffffff; font-family: Arial, Helvetica,Verdana; padding-left:25px; padding-right:25px;">
										<tr>
											<td align="center">
												<br>
												<table class="contenttable" width="85%" border="0" cellspacing="0" cellpadding="0" bgcolor="ffffff" style="color:#3d3963; background-color:#ffffff; font-family: Arial, Helvetica,Verdana; ">
													<tr>
														<td align="center" style="padding-right:25px;">
															<img class="real-width-img" alt="Nearly 80% pain-free" src="images/pain-section-2.png" />
														</td>
														<td>
															<strong>Nearly 80%</strong> of patients treated with BromSite&trade;<br> (vs 55% for vehicle) reported being pain-free on Day 1 postsurgery.<span style="font-size:11px; line-height:0; vertical-align:4px;">10</span>
															<br><br>
															<a href="http://www.bromsite.com/?utm_source=eth-direct&utm_medium=email&utm_content=safety&utm_campaign=IntroducingBrom#safety-data" target="_blank" style="color:#c64d36;">Explore more clinical trial results for BromSite</a><span style="font-size:11px; line-height:0; vertical-align:4px; color:#c64d36;">&trade;</span>.
														</td>
													</tr>
												</table>
											</td>
										</tr>
									</table>
								</div>
								<div class="show-mobile" style="display:none;max-height:0px;overflow:hidden;">
									<table class="mobile-pad show-mobile" border="0" cellspacing="0" cellpadding="0" bgcolor="ffffff" style="color:#3d3963; background-color:#ffffff; padding-left:25px; padding-right:25px; font-family: Arial, Helvetica,Verdana;display:none;">
										<tr>
											<td>
												<br><br>
												BromSite<span style="font-size:11px; line-height:0; vertical-align:4px;">&trade;</span> (bromfenac ophthalmic solution) is the FIRST and ONLY topical ophthalmic nonsteroidal anti-inflammatory drug (NSAID) indicated to prevent ocular pain after cataract surgery.<span style="font-size:11px; line-height:0; vertical-align:4px;">1</span>
												<br><br>
												<strong>Recommended dosing</strong><br>
												One drop of BromSite<span style="font-size:11px; line-height:0; vertical-align:4px;">&trade;</span> should be applied to the affected eye twice daily (morning and evening) 1 day prior to surgery, the day of surgery, and 14 days postsurgery.<span style="font-size:11px; line-height:0; vertical-align:4px;">1</span>
												<br><br>
												<table align="center" class="show-mobile" border="0" cellspacing="0" cellpadding="0" bgcolor="ffffff" style="color:#3d3963; background-color:#ffffff; font-family: Arial, Helvetica,Verdana;display:none;">
													<tr>
														<td>
															<a href="https://www.activatethecard.com/7388/" target="_blank"><img alt="Savings Button" src="images/button-savings.png" /></a>
														</td>
													</tr>
												</table>
												<br><br>
												<strong>Defend against ocular pain and treat inflammation with the penetrating power of BromSite<span style="font-size:11px; line-height:0; vertical-align:4px;">&trade;</span> formulated with the DuraSite<span style="font-size:11px; line-height:0; vertical-align:4px;">&reg;</span> delivery system.<span style="font-size:11px; line-height:0; vertical-align:4px;">1</span></strong>
												<br><br>
												BromSite<span style="font-size:11px; line-height:0; vertical-align:4px;">&trade;</span> is the first and only topical NSAID indicated to prevent ocular pain after cataract surgery.<span style="font-size:11px; line-height:0; vertical-align:4px;">1</span> Formulated with the DuraSite<span style="font-size:11px; line-height:0; vertical-align:4px;">&reg;</span> delivery system to increase ocular retention time, complete coverage is ensured with twice daily dosing.<span style="font-size:11px; line-height:0; vertical-align:4px;">1,2,3,4,5</span>
												<br><br>
												<strong>Indications and Usage</strong>
												<br><br>
												<span style="color:#2c2d2e;">BromSite<span style="font-size:11px; line-height:0; vertical-align:4px;">&trade;</span> (bromfenac ophthalmic solution) 0.075% is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery.</span>
												<br><br>
												<strong>Important Safety Information</strong>
												<br><br>
												<span style="color:#2c2d2e;">&bull; <strong style="color:#3d3963;">Slow or Delayed Healing:</strong> All topical nonsteroidal anti-inflammatory drugs (NSAIDs), including BromSite<span style="font-size:11px; line-height:0; vertical-align:4px;">&trade;</span>, may slow or delay healing. Topical corticosteroids are also known to slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems.</span>
												<br><br>
												<span style="color:#3d3963 font-weight:bold;">See additional Important Safety Information below.</span>
												<br><br>
												<table align="center" class="show-mobile" border="0" cellspacing="0" cellpadding="0" bgcolor="ffffff" style="color:#3d3963; background-color:#ffffff; font-family: Arial, Helvetica,Verdana;display:none;">
													<tr>
														<td>
															<img alt="BromSite icon 1" src="images/icon-power.png" />
														</td>
													</tr>
												</table>
												<br><br>
												The DuraSite<span style="font-size:11px; line-height:0; vertical-align:4px;">&reg;</span> polymer enhances viscosity to increase ocular retention time and reduce medication loss due to blinking and tearing. As DuraSite<span style="font-size:11px; line-height:0; vertical-align:4px;">&reg;</span> mixes with the tear film, the polymer matrix releases bromfenac, which rapidly diffuses across the cornea.<span style="font-size:11px; line-height:0; vertical-align:4px;">3,5</span> The extended release results in improved absorption of bromfenac.<span style="font-size:11px; line-height:0; vertical-align:4px;">3</span>
												<br><br>
												<a href="https://www.bromsite.com/?utm_source=eth-direct&utm_medium=email&utm_content=Learn&utm_campaign=IntroducingBrom#about" target="_blank" style="color:#c64d36; text-decoration:underline; text-decoration:none;"><span style="text-decoration:underline;">Learn more about BromSite&trade;, formulated with the DuraSite</span><sup style="font-size:11px; line-height:0; vertical-align:4px; color:#c64d36; text-decoration:none;">&reg;</sup> <span style="text-decoration:underline;">delivery system.</span></a>
												<br><br>
												<strong>Important Safety Information (continued)</strong>
												<br><br>
												<span style="color:#2c2d2e;">&bull; <strong style="color:#3d3963">Potential for Cross-Sensitivity:</strong> There is the potential for cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other NSAIDs, including BromSite<span style="font-size:11px; line-height:0; vertical-align:4px;">&trade;</span>. Therefore, caution should be used when treating individuals who have previously exhibited sensitivities to these drugs.</span>
												<br><br>
												<span style="color:#2c2d2e;">&bull; <strong style="color:#3d3963">Increased Bleeding Time of Ocular Tissue:</strong> With some NSAIDs, including BromSite<span style="font-size:11px; line-height:0; vertical-align:4px;">&trade;</span>, there exists the potential for increased bleeding time due to interference with platelet aggregation. There have been reports that ocularly applied NSAIDs may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery. It is recommended that BromSite<span style="font-size:11px; line-height:0; vertical-align:4px;">&trade;</span> be used with caution in patients with known bleeding tendencies or who are receiving other medications which may prolong bleeding time.</span>
												<br><br>
												<span style="color:#3d3963; font-weight:bold;">See additional Important Safety Information below.</span>
												<br><br>
												<table align="center" class="show-mobile" border="0" cellspacing="0" cellpadding="0" bgcolor="ffffff" style="color:#3d3963; background-color:#ffffff; font-family: Arial, Helvetica,Verdana; display:none;">
													<tr>
														<td>
															<img alt="BromSite icon 2, Nearly 80% pain-free" src="images/brom-blue-mbl.png" />
														</td>
													</tr>
												</table>
												<br><br>
												<span style="color:#2c2d2e;"><strong style="color:#3d3963">Nearly 80%</strong> of patients treated with BromSite<span style="font-size:11px; line-height:0; vertical-align:4px;">&trade;</span> (vs 55% for vehicle) reported being pain-free on Day 1 postsurgery.<span style="font-size:11px; line-height:0; vertical-align:4px;">10</span></span>
												<br><br>
												<a href="http://www.bromsite.com/?utm_source=eth-direct&utm_medium=email&utm_content=safety&utm_campaign=IntroducingBrom#safety-data" target="_blank" style="color:#c64d36;">Explore more clinical trial results for BromSite</a><span style="font-size:11px; line-height:0; vertical-align:4px;color:#c64d36;">&trade;</span>.
											</td>
										</tr>
									</table>
								</div>
								<table class="mobile-pad" border="0" cellspacing="0" cellpadding="0" bgcolor="ffffff" style="color:#3d3963; background-color:#ffffff; font-family: Arial, Helvetica,Verdana; padding-left:25px; padding-right:25px;">
									<tr>
										<td>
											<br><br>
											<span style="font-weight:bold; color:#3d3963;">Important Safety Information (continued)</span>
											<br><br>
											&bull; <strong>Keratitis and Corneal Effects:</strong> Use of topical NSAIDs may result in keratitis. In some susceptible patients, continued use of topical NSAIDs may result in epithelial breakdown, corneal thinning, corneal erosion, corneal ulceration or corneal perforation. Patients with evidence of corneal epithelial breakdown should immediately discontinue use of topical NSAIDs, including BromSite<span style="font-size:11px; line-height:0; vertical-align:4px;">&trade;</span>, and should be closely monitored for corneal health. Patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse events which may become sight threatening. Topical NSAIDs should be used with caution in these patients. Post-marketing experience with topical NSAIDs also suggests that use more than 24 hours prior to surgery or use beyond 14 days postsurgery may increase patient risk for the occurrence and severity of corneal adverse events.
											<br><br>
											&bull; <strong>Contact Lens Wear:</strong> BromSite<span style="font-size:11px; line-height:0; vertical-align:4px;">&trade;</span> should not be administered while wearing contact lenses. The preservative in BromSite<span style="font-size:11px; line-height:0; vertical-align:4px;">&trade;</span>, benzalkonium chloride, may be absorbed by soft contact lenses.
											<br><br>
											&bull; <strong>Adverse Reactions:</strong> The most commonly reported adverse reactions in 1% to 8% of patients were anterior chamber inflammation, headache, vitreous floaters, iritis, eye pain, and ocular hypertension.
											<br><br>
											<a href="https://www.bromsite.com/pdf/BromSitePI.pdf?utm_source=eth-direct&utm_medium=email&utm_content=PI&utm_campaign=IntroducingBrom " target="_blank" style="color:#c64d36;">Review the full prescribing information here</a>.
											<br><br><br><br>
										</td>
									</tr>
								</table>
								<table class="mobile-pad"  border="0" cellspacing="0" cellpadding="0" bgcolor="ffffff" style="color:#3d3963; background-color:#ffffff; font-family: Arial, Helvetica,Verdana; ">
									<tr style="background:#e5f1f8; ">
									  <td style="padding:25px;">
									    <strong>Sun Ophthalmics is committed to reenergizing eye care</strong><br>
									    By bringing world-class research and development, partnerships, and thoughtful acquisitions, Sun Ophthalmics delivers innovative treatments that integrate easily into your practice. <br><a href="https://sunophthalmics.com/innovation/?utm_source=eth-direct&utm_medium=email&utm_content=Innovation&utm_campaign=IntroducingBrom " target="_blank" style="color:#c64d36;">Learn more about our history of innovation</a>.
									  </td>
									</tr>
								</table>
								<table class="mobile-pad" border="0" cellspacing="0" cellpadding="0" bgcolor="ffffff" style="color:#3d3963; background-color:#ffffff; font-family: Arial, Helvetica,Verdana; padding-left:25px; padding-right:25px; font-size:11px; line-height:15px;">
									<tr>
										<td>
											<br><br>
											<strong>References:</strong>
											<br><br>
											<strong>1.</strong> BromSite<span style="font-size:11px; line-height:0; vertical-align:4px;">&trade;</span> [package insert]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; 2016. <strong>2.</strong> Hosseini K, Hutcheson J, Bowman L. Aqueous humor concentration of bromfenac 0.09% (Bromday<span style="font-size:11px; line-height:0; vertical-align:4px;">&trade;</span>) compared with bromfenac in DuraSite<span style="font-size:11px; line-height:0; vertical-align:4px;">&reg;</span> 0.075% (BromSite<span style="font-size:11px; line-height:0; vertical-align:4px;">&trade;</span>) in cataract patients undergoing phacoemulsification after 3 days dosing. Poster presented at: ARVO Annual Meeting; May 5-9, 2013; Seattle, Washington. <strong>3.</strong> Bowman LM, Si E, Pang J, et al. Development of a topical polymeric mucoadhesive ocular delivery system for azithromycin. <em>J Ocul Pharmacol Ther.</em> 2009;25(2):133-139. <strong>4.</strong> ClinicalTrials.gov. Aqueous humor concentration of lnSite Vision (ISV) 303 (bromfenac in DuraSite) to Bromday once daily (QD) prior to cataract surgery. https://clinicaltrials.gov/ct2/show/results/NCT01387464?sect=X70156&term=insite+vision&rank=1. Accessed July 18, 2016. <strong>5.</strong> Si EC, Bowman LM, Hosseini K. Pharmacokinetic comparisons of bromfenac in DuraSite and Xibrom. <em>J Ocul Pharmacol Ther.</em> 2011;27(1):61-66. <strong>6.</strong> Cho H, Wolf KJ, Wolf EJ. Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution. <em>Clin Ophthalmol.</em> 2009;3:199-210. <strong>7.</strong> Ahuja M, Dhake AS, Sharma SK, et al. Topical ocular delivery of NSAIDs. AAPS J. 2008;10(2):229-241. <strong>8.</strong> Baklayan GA, Munoz M. The ocular distribution of 14C-labeled bromfenac  ophthalmic  solution 0.07% in a rabbit model. <em>Clin Ophthalmol.</em> 2014;8:1717-1724. <strong>9.</strong> Baklayan GA, Patterson HM, Song CK, et al. 24-hour evaluation of the ocular distribution of 14C-labeled bromfenacfollowing topical instillation into the eyes of New Zealand White rabbits. <em>J Ocul Pharmacol Ther.</em> 2008;24(4):392-398. <strong>10.</strong> Data on file. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.
										</td>
									</tr>
								</table>
								<table class="hide-mobile" width="100%" border="0" cellspacing="0" cellpadding="0" bgcolor="ffffff" style="color:#3d3963; background-color:#ffffff; font-family: Arial, Helvetica,Verdana; padding-left:45px; padding-right:45px;">
									<tr>
										<br><br>
										<td align="left">
											<a href="http://www.bromsite.com/?utm_source=eth-direct&utm_medium=email&utm_content=BromLogo&utm_campaign=IntroducingBrom" target="_blank"><img alt="BromSite&trade; logo" src="images/brom-logo-bottom.png"  /></a>
										</td>
										<td align="right">
											<a href="http://www.sunophthalmics.com?utm_source=eth-direct&utm_medium=email&utm_content=BromLogo&utm_campaign=IntroducingBrom" target="_blank"><img alt="Sun Ophthalmics logo" style="padding-bottom:10px;" align="right" src="images/logo_Sun.png"  /></a>
										</td>
									</tr>
								</table>
								<div class="show-mobile" style="display:none;max-height:0px;overflow:hidden;">
								<table class="show-mobile" width="100%" border="0" cellspacing="0" cellpadding="0" bgcolor="ffffff" style="padding-left:25px; padding-right:25px; display:none;max-height:0px;overflow:hidden;">
									<tr>
										<br><br>
										<td align="center" width="50%">
											<a href="http://www.bromsite.com/?utm_source=eth-direct&utm_medium=email&utm_content=BromLogo&utm_campaign=IntroducingBrom" target="_blank"><img class="show-mobile" alt="BromSite&trade; logo" style="display:none;" src="images/brom-logo-bottom.png" /></a>
										</td>
										<td align="center" width="50%">
											<a href="http://www.sunophthalmics.com?utm_source=eth-direct&utm_medium=email&utm_content=BromLogo&utm_campaign=IntroducingBrom" target="_blank"><img class="show-mobile" alt="Sun Ophthalmics logo " style="padding-bottom:10px; display:none;" src="images/logo_Sun.png"  /></a>
										</td>
									</tr>
								</table>
							</div>
								<table class="mobile-pad" align="center" border="0" cellspacing="0" cellpadding="0" bgcolor="ffffff" style="color:#3d3963; background-color:#ffffff; font-family: Arial, Helvetica,Verdana; padding-left:25px; padding-right:25px; font-size:11px; line-height:15px;">
									<tr>
										<td align="center">
											<br><br>
											Sun Ophthalmics is a division of Sun Pharmaceutical Industries, Inc.
											<br><br>
											&copy; 2017 Sun Pharmaceutical Industries, Inc. All rights reserved.<br>
											BromSite and DuraSite are trademarks of Sun Pharma Global FZE.<br>
											SUN-OPH-FRA-036 01/2017
											<br><br><br><br>
										</td>
									</tr>
								</table>
							</td>
						</tr>
					</table>
				</td>
			</tr>
		</table>
	</body>
</html>
